Fertility Counseling in BRCA1/2-Mutated Women with Breast Cancer and Healthy Individuals
- PMID: 35887761
- PMCID: PMC9321124
- DOI: 10.3390/jcm11143996
Fertility Counseling in BRCA1/2-Mutated Women with Breast Cancer and Healthy Individuals
Abstract
Breast cancer is the most commonly diagnosed cancer worldwide and the fifth leading cause of cancer death. In 2020, there were 2.3 million new cases, and 685,000 women died from it. Breast cancer among young women under 40 years of age accounts for 5% to 10% of all cases of this cancer. The greater availability of multi-gene sequence analysis by next-generation sequencing has improved diagnosis and, consequently, the possibility of using appropriate therapeutic approaches in BRCA1/2 gene mutation carriers. Treatment of young breast cancer patients affects their reproductive potential by reducing ovarian reserve. It can lead to reversible or permanent premature menopause, decreased libido, and other symptoms of sex hormone deficiency. This requires that, in addition to oncological treatment, patients are offered genetic counseling, oncofertility, psychological assistance, and sexological counseling. Given the number of BRCA1/2 gene mutation carriers among young breast cancer patients, but also thanks to growing public awareness, among their healthy family members planning offspring, the possibility of benefiting from preimplantation testing and performing cancer-risk-reduction procedures: RRM (risk-reducing mastectomy) and RRSO (risk-reducing salpingo-oophorectomy) significantly increase the chance of a genetically burdened person living a healthy life and giving birth to a child not burdened by the parent's germline mutation. The goal of this paper is to show methods and examples of fertility counselling for BRCA1/2 gene mutation carriers, including both patients already affected by cancer and healthy individuals.
Keywords: BRCA1/2; RRM; RRSO; breast cancer; oncofertility.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464. doi: 10.1002/14651858.CD012464.pub2. Cochrane Database Syst Rev. 2018. PMID: 30141832 Free PMC article. Review.
-
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.Ann Ital Chir. 2019;90:1-2. Ann Ital Chir. 2019. PMID: 30872561
-
Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.Eur J Cancer. 2020 Jun;132:53-60. doi: 10.1016/j.ejca.2020.03.009. Epub 2020 Apr 20. Eur J Cancer. 2020. PMID: 32325420
-
Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.Breast Cancer. 2018 Mar;25(2):141-150. doi: 10.1007/s12282-017-0803-y. Epub 2017 Oct 10. Breast Cancer. 2018. PMID: 29019095
-
[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].Gan To Kagaku Ryoho. 2014 Nov;41(11):1333-9. Gan To Kagaku Ryoho. 2014. PMID: 25434434 Review. Japanese.
Cited by
-
GLS and GOT2 as prognostic biomarkers associated with dendritic cell and immunotherapy response in breast cancer.Heliyon. 2024 Jan 7;10(1):e24163. doi: 10.1016/j.heliyon.2024.e24163. eCollection 2024 Jan 15. Heliyon. 2024. PMID: 38234908 Free PMC article.
-
BRCA Mutations and Fertility Preservation.Int J Mol Sci. 2023 Dec 22;25(1):204. doi: 10.3390/ijms25010204. Int J Mol Sci. 2023. PMID: 38203374 Free PMC article. Review.
-
WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6.Front Pharmacol. 2023 Jan 19;13:1072194. doi: 10.3389/fphar.2022.1072194. eCollection 2022. Front Pharmacol. 2023. PMID: 36744210 Free PMC article.
References
-
- Fredholm H., Magnusson K., Lindström L.S., Garmo H., Fält S.E., Lindman H., Bergh J., Holmberg L., Pontén F., Frisell J., et al. Long-term outcome in young women with breast cancer: A population-based study. Breast Cancer Res. Treat. 2016;160:131–143. doi: 10.1007/s10549-016-3983-9. - DOI - PMC - PubMed
-
- Malone K.E., Daling J.R., Neal C., Suter N.M., O’Brien C., Cushing-Haugen K., Jonasdottir T.J., Thompson J.D., Ostrander E.A. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000;88:1393–1402. doi: 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
